CIBC Private Wealth Group
BIB icon

CIBC Private Wealth Group’s ProShares Ultra NASDAQ Biotechnology BIB Stock Holding History

CIBC Private Wealth Group’s Portfolio BIB Stock Details BIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-60
Closed -$3.83K – 2997
2024
Q3 		$3.83K Hold
60
– – ﹤0.01% 2667
2024
Q2 		$3.58K Hold
60
– – ﹤0.01% 2623
2024
Q1 		$3.41K Buy
+60
New +$3.48K ﹤0.01% 2613

Other funds holding BIB

Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
CIA
Capital Investment Advisors Atlanta, Georgia $6.84B AUM 17.28% 1-Year Est. Return
CIC
Chase Investment Counsel Charlottesville, Virginia $381M AUM 69.8% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return
WWM
Westwood Wealth Management Los Angeles, California $255M AUM 54.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
CCWM
Cassaday & Co Wealth Management Mclean, Virginia $4.69B AUM 20.56% 1-Year Est. Return
PWM
Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return
CWM
Crowley Wealth Management Wilmington, Delaware $126M AUM 23.04% 1-Year Est. Return

CIBC Private Wealth Group's BIB Position: Q4 2024 in Review

CIBC Private Wealth Group sold out of ProShares Ultra NASDAQ Biotechnology (BIB) in Q4 2024, closing a stake of 60 shares — an estimated $3.83K sold.

CIBC Private Wealth Group first reported a position in BIB in Q1 2024 and held it in 3 quarters. The position peaked at $3.83K in Q3 2024. 24 funds tracked by Wall St. Rank hold BIB as of Q4 2024.

  • CIBC Private Wealth Group reported no remaining ProShares Ultra NASDAQ Biotechnology position as of Q4 2024 after selling out during the quarter.
  • CIBC Private Wealth Group sold 60 ProShares Ultra NASDAQ Biotechnology shares in Q4 2024, an estimated $3.83K.
  • CIBC Private Wealth Group first reported a position in ProShares Ultra NASDAQ Biotechnology in Q1 2024 and held it in 3 quarters.
  • CIBC Private Wealth Group's ProShares Ultra NASDAQ Biotechnology position peaked at $3.83K in Q3 2024.
  • 24 funds tracked by Wall St. Rank held ProShares Ultra NASDAQ Biotechnology as of Q4 2024.

Based on CIBC Private Wealth Group's 13F filing for Q4 2024, filed 12 Feb 2025.